Allogeneic cell therapy company Mesoblast (ASX:MSB) has announced expanded US payer coverage for its Ryoncil (remestemcel-L), the first mesenchymal stromal cell therapy approved by the US FDA. …
Mesoblast says Ryoncil payer coverage extended to over 100 million Americans
April 22, 2025 Australian Biotech
Latest Video
New Stories
-
And this is why it's very hard not to be cynical in this system because this committee gets to set its own rules
November 11, 2026 - - Latest News -
The negotiating room is getting smaller as officials narrow the scope
November 11, 2026 - - Latest News -
PBAC sets out its expectations for AI in medicines submissions
November 11, 2026 - -
And this is why it's very hard not to be cynical in this system becasue this committee gets to set its own rules
November 11, 2026 - - Latest News -
Dispatch AI Index finds routine AI use but questions over governance
November 10, 2026 - - News of the Day -
Mayne Pharma sells Salisbury business to Evaris Pharma for $55.5 million
November 10, 2026 - - Latest News -
Bristol Myers Squibb Australia riders more than double their target for Rare Cancers Australia
November 10, 2026 - - Latest News